- 著者
- Chiyo MATSUSHITA Hiroyuki MIZUGUCHI Hitoshi NIINO Yuko SAGESAKA Keisuke MASUYAMA Hiroyuki FUKUI
- 出版者
- Medical and Pharmaceutical Society for WAKAN-YAKU
- 雑誌
- Journal of Traditional Medicines (ISSN:18801447)
- 巻号頁・発行日
- vol.25, no.5+6, pp.133-142, 2008 (Released:2008-12-19)
- 参考文献数
- 61
- 被引用文献数
- 2
ヒスタミンはアレルギー反応における主要メディエーターである。 近年緑茶の抗アレルギー効果が報告されているがヒスタミンシグナルにおける緑茶の効果については明らかでない。 我々は toluene-2, 4-diisocyanate (TDI) 感作により作成した鼻過敏症モデルラットを用いて TDI 発作誘発に伴う鼻粘膜ヒスタミン H1 受容体 (H1R) 及び Th2 サイトカイン mRNA 上昇への緑茶の効果を検討した。 緑茶抽出液を 3 週間連日投与することにより TDI 誘発による鼻粘膜 Th2 サイトカイン mRNA レベル上昇が有意に抑制され H1R mRNA レベルも抑制傾向を示した。 抽出液をカラムクロマトにより分画し, 各画分における効果を検討したところ EGCG が主要成分である TOYOPEARL HW40EC カラム80% ethanol 溶出画分に RBL-2H3 細胞の抗原抗体刺激による Th2 サイトカイン mRNA 上昇の抑制効果が認められた。 EGCG は濃度依存的に IgE 刺激による IL-4 mRNA レベルの上昇及び PMA 刺激による H1R mRNA レベルの上昇を抑制した。 鼻過敏症モデルラットにおいても EGCG の 3 週間連日投与によりくしゃみ回数が減少し TDI 誘発による H1R 及び IL-4 mRNA 上昇が抑制された。 以上の結果より EGCG は鼻過敏症モデルラットの H1R および IL-4 遺伝子発現を抑制することにより IL-4 シグナルだけでなくヒスタミンシグナルも抑制し鼻過敏症症状を軽減することがわかった。
- 著者
- Takao Fujisawa Terufumi Shimoda Keisuke Masuyama Kimihiro Okubo Kohei Honda Mitsuhiro Okano Toshio Katsunuma Atsuo Urisu Yasuto Kondo Hiroshi Odajima Kazuyuki Kurihara Makoto Nagata Masami Taniguchi Shoichiro Taniuchi Satoru Doi Tomoshige Matsumoto Shoji Hashimoto Akihiko Tanaka Kensuke Natsui Nahoko Abe Hideki Ozaki
- 出版者
- Japanese Society of Allergology
- 雑誌
- Allergology International (ISSN:13238930)
- 巻号頁・発行日
- vol.67, no.3, pp.347-356, 2018 (Released:2018-07-28)
- 参考文献数
- 49
- 被引用文献数
- 7
Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.Methods: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria. The treatment period was 52 weeks, and patients who were willing to continue the treatment received TO-204 beyond 52 weeks. This clinical trial is registered at the Japan Pharmaceutical Information Center (Japic CTI-121900).Results: Between July 2012 and May 2015, 44 patients (28 with AR and 16 with allergic BA) were enrolled into the study. All patients were included in the analysis. The duration of treatment ranged from 23 to 142 weeks and the median maintenance dose was 200 Japanese allergy units (JAU). Adverse events occurred in 22 patients (50%). The most common adverse event was local reactions related to the injection sites. Four patients experienced anaphylactic reactions when they were treated with the dose of 500 JAU. Two patients experienced anaphylactic shock with the doses of 1000 JAU at onset. These 6 patients could continue the study with dose reduction.Conclusions: Safety profile of TO-204 was acceptable in Japanese patients with HDM-induced AR or allergic BA. Higher doses should be administered carefully, because the risk of anaphylaxis increased at doses of 500 or 1000 JAU.
- 著者
- Weibin Du Chiharu Fukano Mari Yonemoto Tomokazu Matsuoka Keisuke Masuyama Katsuyo Ohashi-Doi
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Biological and Pharmaceutical Bulletin (ISSN:09186158)
- 巻号頁・発行日
- vol.42, no.4, pp.601-606, 2019-04-01 (Released:2019-04-01)
- 参考文献数
- 29
- 被引用文献数
- 5
Subcutaneous allergen immunotherapy (SCIT) with non-standardized house dust (HD) extracts has been used in Japan since 1963 for house dust mite (HDM)-allergic patients. Since the potencies of HD extracts are unknown, the allergenic potency of HD extracts was examined by comparing with a standardized HDM allergen extracts. The major allergen content of HDM in the extracts was measured using a sandwich enzyme-linked immunosorbent assay (ELISA). The immunoglobulin E (IgE) inhibitory activities of the extracts were measured by a competitive ELISA. The extract concentrations giving 50% inhibition of IgE binding (log10 IC50) were determined from dose–response curves and defined as inhibitory activities. A linear regression line was constructed from the log10 IC50 values of the standardized HDM extract to interpolate the relative potency of the HD extract with strength of 1 : 10 w/v (HD 1 : 10). The amounts of major allergens (Der f 1, Der p 1 and Der 2) were 116.3 µg/mL in the HDM allergen extract (100000 Japanese Allergy Units [JAU]/mL) and 0.77 µg/mL in the HD 1 : 10. The inhibitory activity (log10 IC50 values) of HD 1 : 10 was 2.389 ± 0.078, indicating the allergenic potency was between 200 and 2000 JAU/mL. Based on regression analysis (R2 >0.99), the allergenic potency of HD 1 : 10 was estimated to be 842 ± 128 JAU/mL. The present study determined the major allergen content of HD extract, which contributes to its allergenic potency. The allergenic potency of HD 1 : 10 was ca. 100-fold less than that of HDM allergen extract.
- 著者
- Syuji Yonekura Yoshitaka Okamoto Daiju Sakurai Toshioki Sakurai Tomohisa Iinuma Heizaburou Yamamoto Toyoyuki Hanazawa Shigetoshi Horiguchi Yuichi Kurono Kohei Honda Yuichi Majima Keisuke Masuyama Noriaki Takeda Shigeharu Fujieda Mitsuhiro Okano Satoshi Ogino Kimihiro Okubo
- 出版者
- 一般社団法人日本アレルギー学会
- 雑誌
- Allergology International (ISSN:13238930)
- 巻号頁・発行日
- vol.66, no.3, pp.425-431, 2017 (Released:2017-07-25)
- 参考文献数
- 38
- 被引用文献数
- 13
Background: Complementary and alternative medicine (CAM) is extensively used in patients with allergic diseases worldwide. The purpose of this study was to investigate the actual situation of CAM practice in the treatment of allergic rhinitis.Methods: We distributed questionnaires to otolaryngologists at 114 facilities in Japan. The subjects who participated in this study included children <16 years of age and adults ≥16 years of age diagnosed with allergic rhinitis by otolaryngologists. The survey was performed in the period from September 2007 to August 2009. Furthermore, we performed the same investigation out of the hospital setting, such as during general health examinations. All questionnaires were returned to Chiba University and analyzed.Results: The proportions of patients who had ever experimented with CAM in the hospital survey were 7.1% (225/3170) and 19.2% (1416/7363) of children and adults, respectively. Approximately 36.2% of the adult patients thought that the treatments were effective. The main reasons for CAM use were safety, convenience and low price. However, the group who spent more than $1000 on CAM felt more dissatisfaction and anxiety related to treatment at the hospital. The situation of CAM practice was not consistent and was instead influenced by the backgrounds of the subjects.Conclusions: Many patients who receive CAM report feeling that the effects of treatment provided by hospitals are insufficient and have concerns about the side effects of such treatments. Information regarding standard treatments, as described in the guidelines, should become widely known and diffused, and strong communication with patients should be considered.